3 assets in Rectal Disorder

Therapeutic assets addressing Rectal Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
pf-08634404 Rectal Disorder	Pfizer	P3	B (60)
Capecitabine Rectal Disorder	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	B (57)
Oxaliplatin Rectal Disorder	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (54)